Mr. Lapidus will help advance Lucid’s EsoGuard and EsoCheck commercialization efforts.
Lucid is creating a series of noninvasive diagnostic tests to identify esophageal cancer and Barrett’s esophagus.
Mr. Lapidus said: “Lucid Diagnostics’ EsoGuard and EsoCheck technologies have the potential to be game changers in the diagnosis of conditions along the spectrum from Barrett’s Esophagus to esophageal cancer, which is a growing scourge. … I look forward to working with them as they accelerate commercialization, embark on important IVD clinical trials and explore capital market strategies.”
More articles on ASCs:
The ‘new normal’ for ASCs: 16 admins on how the pandemic will change the field forever
Dr. Thomas Vikoren: Same-day TJR ‘made all the more important’ by COVID-19
Indiana orthopedic practice with surgery center to open
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.